Ipsen SA
Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Semi-annual Revenue
•
in mil. unless spec.Semi-annual Earnings Per Share
•
in mil. unless spec.Semi-annual Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Ipsen S.A. (IPN.PA; IPSEY) is a global biopharmaceutical company focused on developing and commercializing innovative medicines in oncology, rare diseases, and neuroscience; its core products include Somatuline (lanreotide) and Cabometyx (cabozantinib) for neuroendocrine tumors, renal cell carcinoma, hepatocellular carcinoma, and other cancers; Dysport (abobotulinumtoxinA) for spasticity, cervical dystonia, and aesthetics; and Bylvay (odevixibat) and Iqirvo (elafibranor) for rare liver diseases such as progressive familial intrahepatic cholestasis (PFIC) and primary biliary cholangitis (PBC); the company also advances therapies for growth disorders, rare bone diseases, rare neurogenetic disorders, and neurological conditions. Founded in 1929 as Laboratoires Beaufour and headquartered in Paris, France, Ipsen operates in over 88 countries with approximately 5,000 employees and emphasizes partnerships to build its pipeline, targeting patients with high unmet medical needs. Recent developments include the October 2025 announcement of a definitive agreement to acquire ImCheck Therapeutics for up to €1 billion to expand its oncology pipeline with ICT01, a first-in-class gamma delta T-cell activator for hematological malignancies; expansion of partnerships with Marengo Therapeutics (June 2024) and Skyhawk Therapeutics (April 2024) in oncology and neuroscience; positive Phase II LANTIC trial results for IPN10200 in aesthetics (September 2025), enabling Phase III initiation; regulatory approvals for Bylvay in Japan (September 2025) and Cabometyx in the EU for advanced neuroendocrine tumors (July 2025); and strong nine-month 2025 sales growth of 12.1% at constant exchange rates across all therapeutic areas, prompting an upgraded full-year guidance.
Company News
IPSEN (OTCMKTS:IPSEY) Shares Gap Down – Should You Sell?
IPSEN (OTCMKTS:IPSEY) Given Consensus Rating of “Hold” by Analysts
Ipsen S.A. (IPSEY) Q2 2026 Earnings Call Transcript
Ipsen S.A. (IPSEY) Discusses Phase II LANTIC Data and Innovation in Engineered Neuroinhibitors for Aesthetic Indications Transcript
Annual General Meeting of Ipsen S.A. held on 13 May 2026
Ipsen S.A. – Evolution of the composition of the Board of Directors
Ipsen S.A. (IPSEY) Q1 2026 Earnings Call Transcript
IPSEN (OTCMKTS:IPSEY) Shares Cross Above Two Hundred Day Moving Average – Should You Sell?
Ipsen S.A. publishes its 2025 Consolidated Financial Statements
GENFIT to receive US$20M milestone after Ipsen's Iqirvo® exceeds the US$200M threshold in its first full year of net sales
Ipsen S.A. (IPSEY) Q4 2025 Earnings Call Transcript
IPSEN (OTCMKTS:IPSEY) Shares Gap Up – What’s Next?
IPSEN (OTCMKTS:IPSEY) Shares Pass Above Two Hundred Day Moving Average – Time to Sell?
IPSEN (OTCMKTS:IPSEY) Shares Pass Above 200 Day Moving Average – What’s Next?
Ipsen S.A. (IPSEY) Q3 2025 Earnings Call Transcript
Ipsen S.A. publishes its 2025 Half-Year Report (half-year ended 30 June 2025)
Ipsen S.A. - Initiation of the share buy-back program
Ipsen S.A. - Annual General Meeting held on 21 May 2025
GENFIT to receive a €26.5 million milestone payment following the approval of pricing and reimbursement of Ipsen's Iqirvo® in Italy
Ipsen S.A. - Formalities for making available and consulting preparatory documents to the 2025 Annual General Meeting